Skip to main content
. 2019 Jan 16;8(2):527–542. doi: 10.1002/cam4.1940

Table 1.

Univariate analysis of characteristics at first diagnosis and pretreatment blood parameters

60 included patients 25 patients achieving first remission
N (%) 3‐y EFS (95% CI) P value 3‐y OS (95% CI) P value N (%) 3‐y EFS (95% CI) P value 3‐y OS (95% CI) P value
Gender
Female 11 (18) 27.3 ± 26.3 0.327 27.3 ± 26.3 0.802 6 (24) 50.0 ± 40.0 0.599 50.0 ± 40.0 0.471
Male 49 (82) 7.7 ± 7.6 31.9 ± 13.5 19 (76) 19.7 ± 18.6 60.2 ± 23.1
Age [years]
≤10 9 (15) 22.2 ± 27.2 0.201 64.8 ± 32.3 0.175 5 (20) 40.0 ± 42.9 0.494 50.0 ± 69.4 0.225
10‐21 44 (73) 10.9 ± 9.4 26.7 ± 13.1 18 (72) 26.7 ± 21.0 48.9 ± 23.5
≥21 7 (12) 0 16.7 ± 29.8 2 (8) 0 50.0 ± 69.4
Site of primary
Abdominal 56 (93) 6.7 ± 6.7 0.01 27.7 ± 12.2 0.058 21 (84) 17.9 ± 17.1 0.057 54.0 ± 22.3 0.31
Extra‐abdominal 4 (7) 75.0 ± 42.5 75.0 ± 42.5 4 (16) 75.0 ± 42.5 75.0 ± 42.5
Size of primary
<10 cm 18 (30) 16.7 ± 17.2 0.145 35.4 ± 23.3 0.59 7 (28) 42.9 ± 36.7 0.138 83.3 ± 29.8 0.236
≥10 cm 40 (67) 9.4 ± 9.4 30.3 ± 14.7 18 (72) 20.8 ± 19.4 48.5 ± 23.7
No information 2 (3)
Tumor distribution
Localizeda 6 (20) 66.7 ± 37.6 0.004 83.3 ± 29.8 0.001 5 (20) 80.0 ± 35.1 0.005 100% 0.015
Regionally dissem. 16 (27) 6.3 ± 12.0 33.5 ± 23.9 9 (36) 11.1 ± 20.6 55.6 ± 32.5
Extrap. metastases 38 (63) 5.3 ± 7.1 22.1 ± 13.3 11 (44) 18.2 ± 22.7 40.4 ± 30.4
Extraperitoneal metastases in single or multiple organ
No distant mets 22 (37) 22.7 ± 17.4 0.134 47.7 ± 21.4 0.004 14 (56) 35.7 ± 25.1 0.488 71.4 ± 23.7 0.038
Single organ mets 16 (27) 12.5 ± 16.3 27.5 ± 22.5 6 (24) 33.3 ± 37.6 60.0 ± 42.9
Multiple organ mets 22 (37) 0% 18.2 ± 16.1 5 (20) 0% 20.2 ± 35.1
Effusion
No effusion 37 (62) 13.0 ± 11.0 0.005 39.9 ± 16.5 <0.001 18 (72) 26.7 ± 21.0 0.347 57.6 ± 24.1 0.008
Ascites 14 (13) 14.3 ± 18.4 26.8 ± 24.1 5 (20) 40.0 ± 42.9 80.0 ± 35.1
Pleural effusion 3 (5) 0% 0% 2 (8) 0% 0%
Ascites + pleural eff 6 (10) 0% 0% 0 (0)
Venous thrombosis
No 53 (88) 12.6 ± 9.2 <0.001 34.7 ± 13.3 <0.001 23 (92) 29.0 ± 19.2 <0.001 61.8 ± 21.0 <0.001
Yes 4 (7) 0% 0% 2 (8) 0% 0%
No information 3 (5)
Elevation of CRP
No 17 (28) 29.4 ± 21.8 0.002 51.8 ± 24.3 0.009 10 (40) 50.0 ± 31.0 0.011 78.8 ± 26.3 0.052
Yes 37 (62) 4.1 ± 7.1 25.6 ± 14.9 15 (60) 10.0 ± 17.2 41.3 ± 26.7
No information 6 (10)
Thrombocytes > 350/nL
No 40 (67) 14.6 ± 11.2 0.318 32.8 ± 14.9 0.588 17 (68) 34.3 ± 23.1 0.117 63.3 ± 23.5 0.229
Yes 16 (27) 6.3 ± 12.0 34.4 ± 24.1 8 (32) 12.5 ± 22.9 43.8 ± 36.8
No information 4 (6)
Neutrophil‐to‐lymphocyte ratio
<median 24 (40) 15.4 ± 13.9 0.379 41.2 ± 20.0 0.124 11 (44) 22.2 ± 25.1 0.525 68.6 ± 23.7 0.826
>median 26 (43) 11.1 ± 13.3 27.8 ± 18.4 12 (48) 36.4 ± 28.4 56.3 ± 29.0
No information 10 (17) 2 (8)
Platelet‐to‐lymphocyte ratio
<median 27 (45) 18.5 ± 14.7 0.266 35.0 ± 18.4 0.356 13 (52) 25.0 ± 24.5 0.715 51.5 ± 31.0 0.781
>median 27 (45) 11.1 ± 11.8 33.6 ± 18.6 12 (48) 28.8 ± 25.7 61.5 ± 26.5
No information 6 (10)

P values are printed in italics, significant P values are bold (P < 0.05).

a

All with evidence of EWSR1‐WT1 fusion transcript